204 related articles for article (PubMed ID: 28451171)
1. Antiangiogenic platinum through glycan targeting.
Peterson EJ; Daniel AG; Katner SJ; Bohlmann L; Chang CW; Bezos A; Parish CR; von Itzstein M; Berners-Price SJ; Farrell NP
Chem Sci; 2017 Jan; 8(1):241-252. PubMed ID: 28451171
[TBL] [Abstract][Full Text] [Related]
2. Substitution-Inert Polynuclear Platinum Complexes as Metalloshielding Agents for Heparan Sulfate.
Gorle AK; Katner SJ; Johnson WE; Lee DE; Daniel AG; Ginsburg EP; von Itzstein M; Berners-Price SJ; Farrell NP
Chemistry; 2018 May; 24(25):6606-6616. PubMed ID: 29655185
[TBL] [Abstract][Full Text] [Related]
3. Conformational Modulation of Iduronic Acid-Containing Sulfated Glycosaminoglycans by a Polynuclear Platinum Compound and Implications for Development of Antimetastatic Platinum Drugs.
Gorle AK; Haselhorst T; Katner SJ; Everest-Dass AV; Hampton JD; Peterson EJ; Koblinski JE; Katsuta E; Takabe K; von Itzstein M; Berners-Price SJ; Farrell NP
Angew Chem Int Ed Engl; 2021 Feb; 60(6):3283-3289. PubMed ID: 33174390
[No Abstract] [Full Text] [Related]
4. Metalloglycomics.
Farrell NP; Gorle AK; Peterson EJ; Berners-Price SJ
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394023
[TBL] [Abstract][Full Text] [Related]
5. A Comparison of Di- and Trinuclear Platinum Complexes Interacting with Glycosaminoglycans for Targeted Chemotherapy.
Katner SJ; Ginsburg EP; Hampton JD; Peterson EJ; Koblinski JE; Farrell NP
ACS Med Chem Lett; 2023 Sep; 14(9):1224-1230. PubMed ID: 37736178
[TBL] [Abstract][Full Text] [Related]
6. Glycosaminoglycan-directed cobalt complexes.
Christian JM; Zoepfl M; Johnson WE; Ginsburg E; Peterson EJ; Hampton JD; Farrell NP
J Inorg Biochem; 2023 Aug; 245():112254. PubMed ID: 37182504
[TBL] [Abstract][Full Text] [Related]
7. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
8. Heparan sulfate proteoglycan-mediated entry pathway for charged tri-platinum compounds: differential cellular accumulation mechanisms for platinum.
Silva H; Frézard F; Peterson EJ; Kabolizadeh P; Ryan JJ; Farrell NP
Mol Pharm; 2012 Jun; 9(6):1795-802. PubMed ID: 22494465
[TBL] [Abstract][Full Text] [Related]
9. Substitution-inert polynuclear platinum compounds inhibit human cytomegalovirus attachment and entry.
Shoup M; Ourahmane A; Ginsburg EP; Farrell NP; McVoy MA
Antiviral Res; 2020 Dec; 184():104957. PubMed ID: 33132195
[TBL] [Abstract][Full Text] [Related]
10. Non-reducing end labeling of heparan sulfate via click chemistry and a high throughput ELISA assay for heparanase.
Wu ZL; Huang X; Ethen CM; Tatge T; Pasek M; Zaia J
Glycobiology; 2017 Jun; 27(6):518-524. PubMed ID: 28025251
[TBL] [Abstract][Full Text] [Related]
11. FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells.
Reiland J; Kempf D; Roy M; Denkins Y; Marchetti D
Neoplasia; 2006 Jul; 8(7):596-606. PubMed ID: 16867222
[TBL] [Abstract][Full Text] [Related]
12. Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis.
Patel VN; Knox SM; Likar KM; Lathrop CA; Hossain R; Eftekhari S; Whitelock JM; Elkin M; Vlodavsky I; Hoffman MP
Development; 2007 Dec; 134(23):4177-86. PubMed ID: 17959718
[TBL] [Abstract][Full Text] [Related]
13. Use of sulfated linked cyclitols as heparan sulfate mimetics to probe the heparin/heparan sulfate binding specificity of proteins.
Freeman C; Liu L; Banwell MG; Brown KJ; Bezos A; Ferro V; Parish CR
J Biol Chem; 2005 Mar; 280(10):8842-9. PubMed ID: 15632177
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
Naggi A; Casu B; Perez M; Torri G; Cassinelli G; Penco S; Pisano C; Giannini G; Ishai-Michaeli R; Vlodavsky I
J Biol Chem; 2005 Apr; 280(13):12103-13. PubMed ID: 15647251
[TBL] [Abstract][Full Text] [Related]
15. A Fluorogenic Green Merocyanine-Based Probe to Detect Heparanase-1 Activity.
Rabinowitz ZM; Wang Z; Liu J; Zhang Y; Ybargollin AJ; Saketkhou M; Cui L
bioRxiv; 2024 Feb; ():. PubMed ID: 38464176
[TBL] [Abstract][Full Text] [Related]
16. Heparanase: Historical Aspects and Future Perspectives.
Khanna M; Parish CR
Adv Exp Med Biol; 2020; 1221():71-96. PubMed ID: 32274707
[TBL] [Abstract][Full Text] [Related]
17. Testing of potential glycan-based heparanase inhibitors in a fluorescence activity assay using either bacterial heparinase II or human heparanase.
Schoenfeld AK; Vierfuß S; Lühn S; Alban S
J Pharm Biomed Anal; 2014 Jul; 95():130-8. PubMed ID: 24667567
[TBL] [Abstract][Full Text] [Related]
18. On the Biology of Werner's Complex.
de Paiva REF; Peterson EJ; Malina J; Zoepfl M; Hampton JD; Johnson WE; Graminha A; Ourahmane A; McVoy MA; Brabec V; Berners-Price SJ; Farrell NP
Angew Chem Int Ed Engl; 2021 Jul; 60(31):17123-17130. PubMed ID: 34105220
[TBL] [Abstract][Full Text] [Related]
19. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis.
Vlodavsky I; Korner G; Ishai-Michaeli R; Bashkin P; Bar-Shavit R; Fuks Z
Cancer Metastasis Rev; 1990 Nov; 9(3):203-26. PubMed ID: 1705486
[TBL] [Abstract][Full Text] [Related]
20. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation.
Vlodavsky I; Eldor A; Haimovitz-Friedman A; Matzner Y; Ishai-Michaeli R; Lider O; Naparstek Y; Cohen IR; Fuks Z
Invasion Metastasis; 1992; 12(2):112-27. PubMed ID: 1399400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
